Results: Each phase identified: (1) the need to develop a FAP consumer education website and social marketing strategy; (2) the need to develop FAP education materials for MCHNs; (3) development of HP education resources including FAP e-training (including pre-post quiz to assess knowledge change); (4) development of the SmartStartAllergy SMS program (a modification of the SmartVax), to determine behaviour change (particularly for high risk infants) and monitor allergic reactions to common food allergens in those who choose to participate. During all phases, rates of infant anaphylaxis in Western Australia were monitored real-time, through St John Ambulance.
Discussion: The combined phases of the NAS FAP project provide a comprehensive public health approach to implementing the ASCIA Guidelines. This approach assesses resource requirements, trains health professionals and measures knowledge change. The FAP website provides consumer friendly information to encourage uptake of ASCIA Guidelines with a feedback survey in place to assess the website's effectiveness. A social marketing strategy actively promotes resources, while SmartStartAllergy assesses behaviour change and monitors allergic reactions in participants in addition to the state-wide St John Ambulance infant anaphylaxis monitoring. Results: There were 1140 accidental AAI injections (all EpiPen or EpiPen Junior) over the 6 year period (a rate of 2 accidental AAI injections per 1,000 AAI prescription per year). 58% were male, 64% occurred in children, and in most cases the accidental injection was by the allergic child or by their sibling. The majority of cases (95%) were managed at home. Most injections occurred in the thumb/finger (41%), palm (14%) or thigh (5%). Usually no symptoms were reported (55%), although local pain (23%), pallor (8%) and paraesthesia (4%) were not uncommon. PICs usually suggested local measures only (98%) (immersion in warm water and/or massage), and in 1.8% of cases GTN to the affected area was suggested.
Conclusion: Accidental AAI injection is not uncommon and likely underreported. Digits are the most common site injected, but symptoms are mild, and in most cases local measures are only required. We suggest ASCIA Anaphylaxis Action Plans to be updated to contact PICs if accidental AAI injection occurs.
P22 JACK JUMPER ANT ALLERGY IN CHILDREN
John Ainsworth Aim: To ascertain the patient characteristics, geographic location and Jack Jumper ant venom IgE of paediatric patients with Jack Jumper ant allergy reviewed in a tertiary public children's and two private allergy outpatient clinics. To refer all patients (if not already done so) with suspected anaphylaxis for venom immunotherapy.
Method:
We reviewed the medical records of all patients with Jack Jumper ant allergy referred to the Royal Children's Hospital, Epworth Healthcare and Melbourne Allergy Centre and Children's Specialists.
Results: There were 116 patients referred with jack jumper allergy with 227 documented stings. There were 70 confirmed episodes of anaphylaxis. There was no correlation between ssIgE level, co-morbidity and risk of anaphylaxis. The majority of stings occurred in rural Victoria, predominantly in the Central-Northern region. All patients with suspected jack jumper anaphylaxis were referred for venom immunotherapy.
Conclusion: Jack jumper ant allergy is a significant problem in the paediatric population. Venom immunotherapy should be considered for all cases of confirmed anaphylaxis. 
